Tivic Health Systems Inc. (NASDAQ: TIVC) announced it will rebrand as Valion Bio Inc. and change its ticker symbol to VBIO, effective April 28, 2026. The company said the rebrand reflects its transformation from a consumer medical device business to a biopharmaceutical company focused on drug development.

The company's lead drug candidate is Entolimod, a Toll-like receptor 5 agonist being developed as a medical countermeasure for Acute Radiation Syndrome. The drug has received FDA Fast Track and Orphan Drug designations and is being advanced under the FDA's Animal Rule pathway, which allows approval based on animal efficacy data when human trials are not feasible.

Valion Bio is engaged with the Biomedical Advanced Research and Development Authority (BARDA) and other government agencies regarding potential inclusion of Entolimod in the U.S. Strategic National Stockpile. The company stated that over $140 million has been invested in the drug's development over 15 years.

"The Valion Bio name reflects the company we have become," said Chief Executive Officer Michael K. Handley, who was appointed in March 2026. Handley previously served as CEO of Statera Biopharma, where he led advancement of Entolimod.

The company also operates Velocity Bioworks, a contract development and manufacturing organization acquired in December 2025 for approximately $16.3 million. The subsidiary provides manufacturing capabilities for Entolimod and serves third-party biotech clients.

Valion Bio is headquartered in San Antonio, Texas, and is developing Entolimod for both radiation syndrome treatment and potential oncology applications. The company also has a pipeline candidate called Entolasta, described as a next-generation TLR5 agonist.